- Home
- RCKY vs NBTX Comparison
RCKY vs NBTX Comparison
Compare RCKY & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCKY
- NBTX
- Stock Information
- Founded
- RCKY 1932
- NBTX 2003
- Country
- RCKY United States
- NBTX France
- Employees
- RCKY N/A
- NBTX N/A
- Industry
- RCKY Shoe Manufacturing
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- RCKY Consumer Discretionary
- NBTX Health Care
- Exchange
- RCKY Nasdaq
- NBTX Nasdaq
- Market Cap
- RCKY 224.2M
- NBTX 235.6M
- IPO Year
- RCKY 1993
- NBTX 2020
- Fundamental
- Price
- RCKY $30.69
- NBTX $5.19
- Analyst Decision
- RCKY Hold
- NBTX Strong Buy
- Analyst Count
- RCKY 2
- NBTX 2
- Target Price
- RCKY $28.00
- NBTX $11.50
- AVG Volume (30 Days)
- RCKY 41.0K
- NBTX 13.2K
- Earning Date
- RCKY 10-30-2024
- NBTX 10-15-2024
- Dividend Yield
- RCKY 2.08%
- NBTX N/A
- EPS Growth
- RCKY 60.94
- NBTX N/A
- EPS
- RCKY 1.99
- NBTX N/A
- Revenue
- RCKY $462,730,000.00
- NBTX $45,220,186.00
- Revenue This Year
- RCKY $1.34
- NBTX N/A
- Revenue Next Year
- RCKY $5.68
- NBTX N/A
- P/E Ratio
- RCKY $14.92
- NBTX N/A
- Revenue Growth
- RCKY N/A
- NBTX 526.17
- 52 Week Low
- RCKY $11.78
- NBTX $4.14
- 52 Week High
- RCKY $40.14
- NBTX $8.96
- Technical
- Relative Strength Index (RSI)
- RCKY 48.98
- NBTX 50.65
- Support Level
- RCKY $29.48
- NBTX $4.97
- Resistance Level
- RCKY $32.01
- NBTX $5.80
- Average True Range (ATR)
- RCKY 1.16
- NBTX 0.35
- MACD
- RCKY -0.03
- NBTX 0.01
- Stochastic Oscillator
- RCKY 41.69
- NBTX 48.31
About RCKY Rocky Brands Inc.
Rocky Brands Inc acts as a designer, manufacturer, and marketer of premium-quality footwear and apparel. The company's family of brands includes Rocky, Georgia Boot, Durango, Lehigh, Creative Recreation, and the licensed brand Michelin footwear. The company operates its business through three business segments: Wholesale, Retail and Contract. It generates majority of the revenue from Wholesale segment.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.